Over the course of the study, more than 9,000 ID-Cap® System ingestions contributed to a robust assessment of adherence. 84 participants actively used the ID-Cap System for approximately 4 months each. By combining the digital pill data with drug concentrations, the research team was able to accurately quantify tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots (DBS) at each visit according to adherence level¹. Overall, adherence in the study was greater than 90%, and more than 90% of ingestions were detected by the ID-Cap System (as opposed to manually entered)². The study also found that HIV-1 RNA (plasma viral load) remained suppressed (<200 copies/mL) even in cases of intermittent non-adherence, as measured by the ID-Cap System, reinforcing the potential for digital pill technologies in future research on HIV treatment strategies.

This study highlights the growing promise of digital health innovations by both enhancing medication adherence as well as offering critical insights into the effectiveness of ART regimens in real-world settings. 

Nothing in this content constitutes an endorsement by Ryan Coyle or the University of Colorado.

References

1. Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, Coppinger C, Barker N, Ellison L, Zheng JH, Al Zuabi S, Alpert PE, Carnes TC, Buffkin DE Jr, Chai PR, Bushman LR, Kiser JJ, MaWhinney S, Brooks KM, Anderson PL, Castillo-Mancilla JR. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024 Nov 22;79(5):1233-1241. doi: 10.1093/cid/ciae212. PMID: 38636950; PMCID: PMC11581703.
2. Coyle RP, Mainella V, Morrow M, Mann SC, Schwab S, Coppinger C, Barker N, Ellis SL, Carnes TC, Alpert PE, Ellison L, Bushman LR, Brooks KM, MaWhinney S, Castillo-Mancilla JR, Anderson PL. Adherence insights from TAF/FTC-based ART co-encapsulated with an ingestible sensor among virologically suppressed persons with HIV. Coyle RP oral presentation: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, 2024 Sep 18-19; Liverpool, UK. Br J Clin Pharmacol, 90: 10-11. https://doi.org/10.1111/bcp.16291.

The post Recap with ID-Cap®: Monitoring HIV Medication Adherence in University of Colorado’s QUANTI-TAF Study first appeared on etectRx.

The development of a Wrist-Worn Reader is the latest advancement to the ID-Cap System, offering a promising solution to address the complex issue of medication non-adherence.

While the previous ID-Cap component design employed a wearable Reader in the form of a necklace, the evolution of the Wrist-Worn Reader provides a more functional and convenient solution. The Wrist-Worn Reader aims to revolutionize the ID-Cap System component capabilities by catering to different user preferences and lifestyles, making medication adherence technology more adaptable into everyday life. Preliminary testing results of the Wrist-Worn Reader showcase promising results for innovative technology to improve medication adherence and patient care. Read more on the National Institutes of Health (NIH) funded HIV PrEP study here.

The post ID Cap™ System Evolution: Introducing the Wrist-Worn Reader first appeared on etectRx.

etectRx announces record-breaking use of the ID-Cap System, utilized in University of Colorado’s HIV treatment study.

A seamless, end-to-end solution, the ID-Cap is the only ingestible sensor solution which allowed the study’s researchers to monitor, track, trend, report, and provide real-time, accurate data through etectRx’s core technology, eBurst. When nonadherence was detected by the ingestible sensor technology, University of Colorado researchers were able to intervene in a timely fashion to send real-time dosing reminders to patients’ smartphone apps.

QUANTI-TAF began in August 2020, and the last follow-up concluded in May 2023. A total of 84 participants were enrolled in the study for up to 4 months each, resulting in 8,910 expected ingestions over 9,049 days monitored, and a cumulative adherence rate of 95%. The QUANTI-TAF study showed consistently high acceptability of the ID-Cap System over time, as participants used it for up to approximately 112 days (4 months).

Data from University of Colorado’s QUANTI-TAF study demonstrates significant milestones for the ID-Cap System with a reputation for demonstrating strong results and providing data to accurately track patients’ adherence to their oral medications. “The ID-Cap System was central to our QUANTI-TAF study; we used the digital pill data to establish adherence benchmarks for our drug concentrations, which was a key outcome of our study,” said Peter Anderson, PharmD- Antiviral Pharmacology, Professor at University of Colorado Anshutz Medical Campus.

etectRx gained FDA clearance for its innovative ID-Cap System technology in December 2019. Since FDA clearance, the technology has generated strong, accurate results across multiple indications, particularly with patient populations with traditionally poor levels of medication adherence, including those with substance abuse disorders.

About etectRx

etectRx is a digital health company. The FDA-cleared ID-Cap System uniquely addresses the issue with adherence to (oral) medication. The accurate, flexible, and simple digital pill system allows researchers, pharmacists, physicians, and pharmaceutical companies to rethink approaches to medication adherence, innovate with confidence, and accelerate patient outcomes. To learn more, visit https://etectrx.com/.

The post ID-Cap™ System Powers Historic HIV Digital Pill Study first appeared on etectRx.

Liege, Belgium (APRIL 28th, 2022) – Belgium-based AARDEX® Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s ingestible event marker, the ID-Cap System, and AARDEX® Group’s MEMS® Adherence Software (MEMS AS®) to track medication-taking behaviors. Together, they provide a holistic, objective, and precise method to measure and manage adherence to solid form dose medications.

etectRx, Inc joins other partners as part of AARDEX® Group’s ever-growing, robust ecosystem of Medication Adherence Hardware. The FDA-cleared ID-Cap System features a capsule with an embedded ingestible wireless sensor, called the ID-Tag. When swallowed, the sensor transmits a low-power digital message from inside the stomach. Under the AARDEX® Group integration, the captured data can be transmitted to the MEMS AS®, software which harnesses proprietary algorithms to help sponsors understand patient dosing patterns. Healthcare teams can then use this information to risk-stratify patients, deliver targeted interventions, and boost medication adherence.

Since COVID-19 reshaped the research industry, there has been an uptick in the need for solutions that can allow sponsors to deliver trials remotely. In this scenario, where some or all in-person visits are off the table, poor medication adherence could present as an issue. Medication non-adherence leads to poor outcomes in routine care and can jeopardize the success of clinical research. The pharmaceutical industry needs data-driven solutions that will help patients remain adherent to their oral medications. This is particularly true in clinical trials, where the primary source of trial failure is an inability to demonstrate efficacy.[1]

Bernard Vrijens, CEO & Scientific Lead, AARDEX, comments: “We are delighted to add etectRx to our growing, global medication adherence ecosystem. By linking our medication monitoring software to their ingestible sensors, we are adding a valuable partner to our global ecosystem of smart packages and devices to cover all routes of drug administration.

At AARDEX®, we believe improving healthcare outcomes is about team collaboration, which is why we have an active focus on partnering with industry leaders like etectRx.”

Eric Buffkin, President and CEO of etectRx adds: “etectRx recognizes the deep experience and expertise of the AARDEX team and their passion to improve medication adherence. The combination of our ID-Cap System feeding real-time, confirmed dosing information to AARDEX’s suite of adherence software will provide a powerful tool for biopharma and CRO’s.”

[1] Fogel, D. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092479/

The post AARDEX® Group Adds etectRx to their MEMS® Adherence Hardware Ecosystem first appeared on etectRx.

The post WHITEPAPER: The Extraordinary Problem of Medication Nonadherence in Oncology Patients And How Digital Pills Can Make a Difference first appeared on etectRx.

The post etectRx “It Already Does That” first appeared on etectRx.

In this video, Dr. Jose Castillo-Mancilla speaks about the importance of the connection between patients and clinicians that the ID-Cap System facilitates, as well as the importance that medication adherence has on clinical outcomes.

The post The ID-Cap™ System: A Physician’s Perspective first appeared on etectRx.

The study was a prospective, single-arm, open-label study at 18 US academic and community clinics. All participants had at least one risk factor for non-adherence, and the majority of patients studied had Medicaid coverage (64.92%) and psychiatric disorders (61.1%).

Study Highlights:

• HCV cure (ie. SVR) was achieved in 99.1% of 218 participants who received direct-acting antivirals for 8-12 weeks, used the DMP and had SVR assessed at ≥10 weeks post-treatment
• Overall pill-taking adherence was 95.0% (57.1%, 100%)
• Participants rated the system as useful and easy to use through satisfaction surveys

This is promising data for digital pills. etectRx’s ID-Cap System is another solution that can assist in the fight for adherence in populations at high risk for nonadherence. Watch the ID-Cap demo to see our technology.

Treatment adherence is critical to obtaining HCV cure with these antivirals, especially in vulnerable populations, and to achieving the goal of World Health Organizations eliminating HCV as a public health threat by 2030.

The post Digital Pill Study Shows Significant Impact on Hepatitis C Treatment Adherence and Efficacy first appeared on etectRx.

The post Failure Risk in Clinical Trials? An Easy-to-Swallow Solution first appeared on etectRx.

The webinar, moderated by Stefanie Kuhner of Bristol-Myers Squibb, had 81 registrants from across the pharma and clinical world. Just as attendees learned about etectRx and our digital pill technology, etectRx learned from webinar participants.

During the discussion, etectRx polled the audience, concluding that 89% of participants said their opinions of digital pills and digital pill systems was positive because of the presentation. The majority of listeners saw digital pill systems positively in real and current time.

The majority of registrants also disclosed that their companies are not currently evaluating digital pill systems, with one-third of webinar participants recording that they would be advocates for a demonstration project using a digital pill system.

To hear more details about our technology and our current clinical exposure, register and watch “Better Connections with Patients Using Data from Digital Pills” on Xtalks, or watch the individual speaker sessions below.

Contact the team at info@etectRx.com to learn how to schedule a demonstration project today.

Stay updated with etectRx. Subscribe to our newsletter here.
 

Susan’s Discussion:

Peter’s Discussion:

Patient Testimonial

The post Better Connections with Patients Using Data from Digital Pills first appeared on etectRx.